6 - 甲基-1,1' - [2 - (5 - 甲基- 2-苯基- 4-恶唑基)乙基] - 螺[4H - 3-1,1 - 苯并恶嗪- 4,4' -哌啶]-2(1H)-酮
| 中文名称 | 6 - 甲基-1,1' - [2 - (5 - 甲基- 2-苯基- 4-恶唑基)乙基] - 螺[4H - 3-1,1 - 苯并恶嗪- 4,4' -哌啶]-2(1H)-酮 |
|---|---|
| 中文同义词 | 6 - 甲基-1,1' - [2 - (5 - 甲基- 2-苯基- 4-恶唑基)乙基] - 螺[4H - 3-1,1 - 苯并恶嗪- 4,4' -哌啶]-2(1H)-酮;6-甲基-1'-[2-(5-甲基-2-苯基-4-恶唑基)乙基]螺[4H-3,1-苯并恶嗪-4,4'-哌啶]-2(1H)-酮;6-甲基-1'-[2-(5-甲基-2-苯基-噁唑-4-基)乙基]-螺[4H-3,1-苯并噁嗪-4,4'-哌啶]-2(1H)-酮;6-甲基-1'-(2-(5-甲基-2-苯基恶唑-4-基)乙基)螺[苯并[D][1,3]恶嗪-4,4'-哌啶]-2(1H)-酮;化合物RS 504393;6-甲基-1'-(2-(5-甲基-2-苯基恶唑-4-基)乙基)螺[苯并[D][1,3]恶嗪-4,4'-哌啶]-2(1H)-一;6 - 甲基-1,1' - [2 - (5 - 甲基- 2-苯基- 4-恶唑基)乙基] - 螺[4H - 3-1,1 - 苯并恶嗪- 4,4' -哌啶]-2(1H)-酮 1级;RS504393,CCR2趋化因子受体拮抗剂 |
| 英文名称 | RS 504393 |
| 英文同义词 | Spiro[4H-3,1-benzoxazine-4,4'-piperidin]-2(1H)-one, 6-Methyl-1'-[2-(5-Methyl-2-phenyl-4-oxazolyl)ethyl]-;6-Methyl-1'-[2-(5-Methyl-2-phenyl-4-oxazolyl)ethyl]-spiro[4H-3,1-benzoxazine-4,4'-piperidi;6-Methyl-1'-(2-(5-Methyl-2-phenyloxazol-4-yl)ethyl)spiro[benzo[d][1,3]oxazine-4,4'-piperidin]-2(1H)-one;6-Methyl-1'-(2-(5-methyl-2-phenyloxazol-4-yl)ethyl)spiro-[benzo[d][1,3]oxazine-4,4'-piperidin]-2(;6-Methyl-1'-(2-(5-methyl-2-phenyloxazol-4-yl)ethyl)spiro-[benzo[d][1,3]oxazine-4,4'-piperidin];RS 504393;6-Methyl-1'-[2-(5-methyl-2-phenyl-4-oxazolyl)ethyl]-spiro[4H-3,1-benzoxazine-4,4'-piperidin]-2(1H)-one;RS-504393; RS504393 |
| CAS号 | 300816-15-3 |
| 分子式 | C25H27N3O3 |
| 分子量 | 417.5 |
| EINECS号 | |
| 相关类别 | 定制化学品 |
| Mol文件 | 300816-15-3.mol |
| 结构式 | ![6 - 甲基-1,1' - [2 - (5 - 甲基- 2-苯基- 4-恶唑基)乙基] - 螺[4H - 3-1,1 - 苯并恶嗪- 4,4' -哌啶]-2(1H)-酮 结构式](CAS/GIF/300816-15-3.gif) |
6 - 甲基-1,1' - [2 - (5 - 甲基- 2-苯基- 4-恶唑基)乙基] - 螺[4H - 3-1,1 - 苯并恶嗪- 4,4' -哌啶]-2(1H)-酮 性质
| 密度 | 1.28 |
|---|---|
| 储存条件 | 2-8°C |
| 溶解度 | DMSO：可溶1mg/mL，澄清（加热） |
| 形态 | 粉末 |
| 颜色 | 白色至米色 |
|
CCR2 89 nM (IC 50 ) |
Human α 1a receptor 72 nM (IC 50 ) |
Human α 1d receptor 460 nM (IC 50 ) |
5HT-1a receptor 1070 nM (IC 50 ) |
RS 504393 inhibits the MCP-1-induced chemotaxis with an IC 50 of 330 nM. RS 504393 treatment suppresses allergen induced β-hexosaminidase release significantly. Without allergen priming, MCP-1 induces mast cell degranulation, which is completely suppressed by RS 504393.
RS504393 (0.3-3 μg) with CCL2 progressively blocks thermal hyperalgesia dose-dependently in mice. RS 504393 (5 mg/kg, i.v.) supresses the elevated numbers of leukocytes and increased total protein content in BALF induced by The LPS. RS504393 significantly down regulates the LPS-induced elevation of IL-1β, PAI-1 mRNA and protein expressions. RS504393 significantly suppresses induced lung edema, protein-rich fluid, polymorphonuclear accumulation and bronchial wall thickening induced by LPS. RS-504393 significantly reduces renal pathology, especially the extensive interstitial fibrosis mediated by decrease in type I collagen synthesis in a UUO model.
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2024/04/30 | HY-15418 | RS 504393 | 1 mg | 324元 | |
| 2024/04/30 | HY-15418 | 6 - 甲基-1,1' - [2 - (5 - 甲基- 2-苯基- 4-恶唑基)乙基] - 螺[4H - 3-1,1 - 苯并恶嗪- 4,4' -哌啶]-2(1H)-酮 RS 504393 | 300816-15-3 | 5mg | 810元 |